FindTrial
Sign In

To explore the prognostic value of PET/CT imaging combined with clinical indicators in mantle cell lymphoma

To explore the prognostic value of PET/CT imaging combined with clinical indicators in mantle cell lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089361
Enrollment
Unknown
Registered
2024-09-06
Start date
2024-09-15
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mantle Cell Lymphoma

Interventions

group of lymphoma:None

Sponsors

Department of Nuclear Medicine, West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Pathological histology confirmed as Mantle Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

Exclusion criteria

Exclusion criteria: 1. The patient had previously received antitumor therapy; 2. The patient had a history of other tumors; 3. Incomplete clinical information or imaging data; 4. Concomitant other malignant tumors.

Design outcomes

Primary

MeasureTime frame
receiver operating characteristic curve, ROC;Progression-Free Survival;Overall Survival;—

Countries

China

Contacts

Public ContactRong Tian

Department of Nuclear Medicine, West China Hospital of Sichuan University

rongtiannuclear@126.com+86 189 8060 1586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026